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an open access articAbstract To assess targeting of an epothilone folate conjugate (BMS-753493) to the folate receptor
(FR)-overexpressed tumor in mice bearing both FRþ and FR– tumors, a series of experiments were
conducted by quantitative whole-body autoradiography (QWBA) and LC–MS/MS following i.v.
administration of BMS-753493 or its active moiety, BMS-748285 in mice bearing FRþ (98M109) and
FR– (M109) tumors. QWBA showed [3H]BMS-753493–derived radioactivity was extensively distributed
to various tissues. The FR over-expressing 98M109 tumors showed consistently higher level of
radioactivity than FR-negative tumors (i.e., M109 tumors) up to 48 h post dose of [3H]BMS-753493,
despite the magnitude of difference between the tumors is relatively small (generally 35-fold). The
radioactivity level in 98M109 tumors was 212-fold of normal tissues except intestine/content at 48 h
post dose. No selective radioactivity uptake into 98M109 tumors over M109 or normal tissues was
observed after i.v. administration of the active epothilone, [3H]BMS-748285. LC–MS/MS measurements
demonstrated that the concentrations of BMS-748285, presumably from hydrolysis of the folate conjugate,
in 98M109 tumors were greater than those in M109 tumors after i.v. administration of BMS-753493 (2–3-
fold) whereas no differential uptake in the tumors following BMS-748285 administration. Those data
were consistent with radioactivity determinations. Those results demonstrated that the folate conjugation
in BMS-753493 enabled moderately preferential distribution of the active epothilone to FR over-
expressing 98M109 tumors, thereby supporting targeted delivery of cytotoxics through the folate receptor.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).9
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Folic acid (folate, vitamin B9) is an essential nutrient that is
involved in many metabolic pathways, including amino acid
interconversions and nucleotide synthesis in normal and proliferat-
ing cells1. Folate receptor (FR), a family of glycosylphosphatid-
ylinositol-linked proteins, captures folate and other ligands from the
extracellular milieu and transports them inside the cell via a non-
destructive, recycling endosomal pathway. Two membrane folate
receptors (FRα and FRβ) and two soluble receptors (FRγ and FRδ)
have been identiﬁed. Both FRα and FRβ are functional for high-
afﬁnity folate binding, although they can display some differences
in their binding afﬁnity for reduced folate cofactors or antifolates2,3.
Surprisingly, FR is expressed on few cell types. FRα is detected on
the apical surfaces of several epithelial cells where it is inaccessible
to parenterally administered folate conjugates. FRβ, in contrast, is
expressed on activated macrophages. FRγ and FRδ have been
difﬁcult to detect in human tissues3–6.
Elevated expression of FRα occurs in many human malignan-
cies, as in the case of ovarian, endometrial, renal, lung and breast
carcinomas, especially when associated with aggressively growing
cancers2. Non-mucinous ovarian cancer, which represents the
majority of ovarian cancers, was the ﬁrst tumor type to be
associated with FR “over-expression”7,8. Importantly, conjugation
of molecules to folic acid does not normally interfere with the high
afﬁnity (Kdo1 nmol/L) of folate for its receptor nor with its
endocytosis into cells9. Folate conjugates undergo internalization
via receptor-mediated endocytosis, delivering the folate-linked
drugs with high afﬁnity into the cell interior, and with a proper
linker, the active drug can be released under the acidic condition in
the endosome10,11. Taken together, FR-targeted strategies could
have a signiﬁcant impact on cancer treatment for patients
diagnosed with FR-positive (FRþ) disease.
BMS-753493 is a novel epothilone folate conjugate which is
designed to target FR over-expressing tumors. As shown in Fig. 1, a
molecule of BMS-753493 contains an active epothilone, BMS-
748285, a folate moiety, and a peptide linker with a disulﬁde bond
tethering the epothilone piece. The mechanism of action of the
epothilone folate conjugate is presumably through tight binding of the
folate moiety to FRα receptor on the target cell surface, followed by
endocytosis of the receptor–ligand complex, and subsequent cleavage
of the linker to release the active epothilone. BMS-753493 demon-
strated antitumor activity in various experimental mouse xenograft
models where folate receptor was over-expressed12. By targeting the
folate receptor, BMS-753493 is expected to provide preferential
distribution of BMS-748285 into the FRþ tumors in comparison with
FR negative (FR–) tumors or normal tissues, thereby improving the
therapeutic index of cancer treatment. However, tissue distribution
and tumor concentration of BMS-753493 and BMS-748285 relative
to plasma and other normal tissue concentrations are unknown.
The goal of this study was to investigate the distribution of
radioactivity after a single i.v. injection of [3H]BMS-753493 and
[3H]BMS-748285 at molar equivalent doses to CD2F1 mice bearing
bilateral subcutaneous murine lung tumors 98M109 (FRþ) and
M109 (FR–) at left or right ﬂank of animal using quantitative whole
body autoradiography (QWBA). Further experiments werenCorresponding author at: Pharmaceutical Candidate Optimization, Bristol-My
252 7785; fax: þ1 609 252 6802.
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Peer review under responsibility of Institute of Materia Medica, Chinese Acperformed to measure BMS-748285 levels in plasma, tumors, and
representative normal tissue samples using LC–MS/MS assays after
administration of unlabeled BMS-753493 and BMS-748285.2. Materials and methods
2.1. Chemicals
[3H]BMS-753493 (20.5Ci/mmol) and [3H]BMS-748285 (21.3Ci/
mmol) were supplied by Radiochemistry Group of Department of
Chemical Synthesis, Bristol-Myers Squibb (Princeton, NJ, USA).
Radiochemical purity of the compounds was determined to be 4
99% by radio-HPLC. The chemical structures of BMS-753493 and
BMS-748285 are shown in Fig. 1. Unlabeled BMS-753493 and
BMS-748285 were supplied by the Process Research and Devel-
opment, Bristol-Myers Squibb (New Brunswick, NJ, USA). All
other chemicals were purchased from Sigma–Aldrich (St. Louis,
MO, USA) unless stated in the text.
2.2. Cell culture
Folate receptor-positive Madison 109 (98M109) lung carcinoma
cells were cultured in folate-deﬁcient RPMI 1640 medium with
10% fetus bovine serum at 37 1C in a 5% CO2 humidiﬁed
atmosphere. Folate receptor negative Madison 109 (M109 cells)
were cultured in normal RPMI 1640 medium under similar
conditions before inoculation.
2.3. Animal models and tumors
Six- to eight-week old CD2F1 female mice were used in these
studies. Mice were purchased from Harlan Sprague Dawley, Inc.
(Indianapolis, IN, USA) and maintained in a speciﬁc pathogen free
facility at Bristol-Myers Squibb Research and Development with
food and water ad libitum. All animal experiments were done
under a protocol approved by the Bristol-Myers Squibb Animal
Care and Use Committee.
A tumor brei (2%, w/v) of M109 and 98M109 tumor cells were
inoculated in the subcutaneous space of the mouse right and left
ﬂank of CD2F1 mice, respectively. High expression of FRα in
98M109 cells has been detected and conﬁrmed (unpublished data).
The xenografts were allowed to grow for two weeks after
inoculation before being used in these distribution experiments.
The approximate size of each tumor was around 100 mg at the
time of dosing.
2.4. Tissue distribution study of radiolabeled BMS-753493 and
BMS-748285
[3H]BMS-753493 or [3H]BMS-748285 was administered intrave-
nously though tail vein injection at a dose level of 2.2 nmol/kg (4
and 1.2 mg/kg for BMS-753493 and BMS-748285, respectively;
10 mCi/kg) into M109 and 98M109 tumor-bearing mice for
biodistribution experiments (n¼4 in each treatment). Theers Squibb, PO BOX 4000, Princeton, NJ 08543-4000, USA. Tel.: +1 609
ademy of Medical Sciences and Chinese Pharmaceutical Association.
Figure 1 Chemical structures of [3H]BMS-753493 and [3H]BMS-
748285.
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Both agents were efﬁcacious in 98M109 tumors at this dose.
[3H]BMS-753493 dosing solution was freshly prepared in Del-
becco's phosphate saline buffer just prior to dosing, and
[3H]BMS-748285 solution was prepared freshly in a vehicle of
cremphor:ethanol:5% dextrose water (1:1:8, v/v/v). One animal
from each treatment was euthanatized at 0.5, 2, 24, and 48 h post-
dose and immediately frozen in a dry ice-hexane bath (–70 1C) for
10 min. The distribution of radioactivity in animal at various times
was determined by quantitative whole-body autoradiography as
described as following.2.5. Quantitative whole-body autoradiography (QWBA)
The frozen carcasses were rapidly stored below –20 1C until
embedment in an ice-cold solution of 2% carboxymethylcellulose
with a microtome stage. They were then frozen in a dry ice–
hexane bath at –70 1C for approximately 60 min, followed by an
overnight at –20 1C. Whole-body sections were obtained in a
Leica CM3600 crymicrotome (Leica microsystems, Nussloch,
Germany) at 40 mm thick in the sagittal plane. Sections were
captured on adhesive tape (Scotch Tape No. 8210, 3M Ltd., St.
Paul, MN, USA) at –20 1C. Sections at various levels were
collected to include the major tissues and tumor, and then were
dried in the cryomicrotome at –20 1C for 48 h. The sections of
each animal was mounted on a cardboard, covered with a thin
plastic wrap, and exposed along with calibration 3H-standards
(range from 0.04 to 13 nCi/mg) to a 3H-sensitive phosphor
imaging plate (Fuji Biomedical, Stamford, CT, USA) in light-
tight exposure cassettes for 3 weeks at room temperature in a lead
shielding box. After exposure, the imaging plates were scanned
using Fuji 3000 image acquisition system (Fuji Biomedical). The
image ﬁles were processed using MCIDTM image analysis soft-
ware (v.7.0, Imaging Research, Inc., St. Catherines, Ontario,
Canada) and a standard curve was constructed from the integrated
response and the radioactivity concentrations of the[3H]-calibration standards. The concentrations of radioactivity
were expressed as the mg equivalents of parent compound per
gram sample (mg eq/g). A lower limit of quantiﬁcation (LLQ) was
applied to the data. The LLOQ were determined by using the
radioactive concentration of background without tissues.
2.6. Tissue distribution and pharmacokinetics study of unlabeled
BMS-753493 and BMS-748285
BMS-753493 or BMS-748285 was administered intravenously
though tail vein injection at a dose level of 2.2 nmol/kg (4 and
1.2 mg/kg for BMS-753493 and BMS-748285, respectively) into
the tumor-bearing CD2F1 mice (n¼9 in each treatment; n¼3 at
each time point). BMS-753493 and BMS-748285 dosing solutions
were prepared as described in the previous section. The blood
samples were collected at 2, 6, and 24 h post dose by direct cardiac
puncture using vacutainers containing K3EDTA as an anticoagu-
lant and 250 mmol/L phenylmethylsulphonylﬂuoride (PMSF)/
methyl acrylate (1:1, v/v) as an stabilizer cocktail. The volume
ratio of stabilizer cocktail versus blood was 1:50. Blood was
centrifuged at 2000 g for 5 min at 4 1C to obtain plasma, which
was frozen immediately and stored at –20 1C until analyzed.
Kidney, heart, and tumor tissue samples were collected and
weighed, and were then frozen and stored at –70 1C until LC–
MS/MS analysis.
2.7. Determination of test compounds by LC–MS/MS
The concentration of test compounds in plasma, heart, kidney, and
tumors were determined by LC–MS/MS, as described as below.
2.7.1. Plasma
Plasma samples (50 μL) were mixed well with appropriate
amounts of internal standard working solution containing
[13C2D4]BMS-753493 and [
13C2D4]BMS-748285 in methanol in
a 96-well Sirocco protein precipitation polypropylene plate
(Waters, Milford, MA, USA). The plates were centrifuged at
2000 g for 12 min at room temperature, and 20 μL ﬁltrate was
injected for LC–MS/MS analysis.
2.7.2. Heart, kidney and tumor samples
Heart, kidney, or tumors were transferred separately to test tubes,
cut into small pieces using a scissors, and then homogenized in
phosphate buffered saline (PBS) solution containing 3.3 mmol/L
of PMSF in a ratio of 1:3 (w/v). Each homogenate (50 μL) was
mixed well with 100 μL of internal standard working solution
containing [13C2D4]BMS-753493 and [
13C2D4] BMS-748285 in
methanol into a 96-well Sirocco protein precipitation polypropy-
lene plate. The plate was centrifuged at 2000 g for 12 min at
room temperature, and 20 μL each ﬁltrate was injected for LC–
MS/MS analysis.
2.7.3. LC–MS/MS analysis
LC–MS analysis of BMS-753493, BMS-748285, and their internal
standards was performed on a Sciex API 4000 mass spectrometer
(Applied Biosystems, Foster City, CA, USA). High performance
liquid chromatography (HPLC) consisted of three Shimadzu LC-
10AD pumps with a SCL-10AVP system controller (Tokyo,
Japan) and a CTC Analytics HTS PAL autosampler equipped
with a cooling stack maintained at 5 1C (LEAP, Carrboro, NC,
USA). The column used was a Luna C18(2) (2.0 mm  50 mm,
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate 4633 μm, Phenomenex, Torrance, CA, USA) maintained at ambient
temperature. Mobile phase A was water containing 10 mmol/L
ammonium formate and 1.0% formic acid. Mobile phase B was
10 mmol/L ammonium formate and 1.0% formic acid in acetoni-
trile:water (90:10, v/v). HPLC ﬂow rate was 0.3 mL/min and a
linear gradient was run from 15% B at 0 min to 70% B at 2 min,
held for 1 min and ramped back to 15% in 0.1 min. The total run
time was 4 min. For each run, the ﬂow from 1.2 to 2.2 min was
delivered to the mass spectrometer. The rest was diverted to waste
while a make-up ﬂow consisting of 10 mmol/L ammonium
formate and 1.0% formic acid in 11:9 (v/v) water: acetonitrile
was delivered to mass spectrometer with a ﬂow rate of 0.3 mL/
min. The HPLC was interfaced with an API 4000 mass spectro-
meter equipped with an electrospray ionization source in the
positive ion mode. The Turbospray probe temperature was 500 1C
and the spray voltage was 4000 V. Ultra high purity nitrogen was
used as the Gas 1, Gas 2, curtain gas and collision gas at ﬂow rates
of 30, 60, 30 and 12 (arbitrary unit), respectively. Multiple
reactions monitoring (MRM) was used for detection. For BMS-
753493 and its internal standard, the parent ions were the doubly
charged ion [Mþ2H]2þ. The MRM transitions for BMS-753493
and BMS-748285 were m/z 785.3 to m/z 295.1 and m/z 537.3 to m/
z 349.2, respectively. The MRM transitions for internal standard
[13C2D4]BMS-753493 and [
13C2D4]BMS-748285 were m/z 788.3
to m/z 295.1 and m/z 543.0.3 to m/z 355.0, respectively. The linear
ranges were 1–500 and 10–5000 ng/mL, respectively, for BMS-
748285 and BMS-753493.2.8. Statistical analysis
Paired Student's t-test was used for comparison of mean cold
BMS-748285 levels in various tumors and tissues.Figure 2 Autoradiograms of selected sections of mice at 48 h after
dosing with [3H]BMS-753493. The representative whole-body auto-
radiograms of tumor-bearing mice following i.v. dose (2.2 nmol/kg or
4 mg/kg) of [3H]BMS-753493 at 48 h. The sections were to compare
radioactivity distribution in M109 (FR–, right side) and 98M109 (FRþ,
left side) tumors, and selected tissues. Details of whole-body auto-
radiography are described in the Section of Materials and methods.3. Results
3.1. QWBA after administration of [3H]BMS-753493
The radioactivity was well visualized and quantiﬁed by whole body
autoradiography in the tumor-bearing mice. Fig. 2 presents the
quantitative tissue distribution of radioactivity from [3H]BMS-753493
at 48 h after i.v. administration of [3H]BMS-753493. In addition to
tumors, [3H]BMS-753493-derived radioactivity was extensively dis-
tributed in a large variety of normal tissues with the highest
concentrations in the gastrointestinal tract/content, liver, kidney, heart
and bone marrow. Very little radioactivity was observed in the brain
and spinal cord (Fig. 2 and Table 1). Interestingly, most of the
radioactivity in the tumors was observed in the peripheral region and
essentially no radioactivity in the core of tumors, indicating that the
drug was not well perfused in the tumors (Fig. 3). Because of the
heterogeneous distribution, the radioactivity in tumors was calculated
from the peripheral region only.
The uptake into the FR overexpressing tumor 98M109 was
greater than that in M109 tumors at all time intervals despite of
only 3.4- to 4.5-fold difference in radioactivity from
[3H]BMS-753493 observed (Fig. 3 and Table 1). The radioactivity
of 98M109 tumor tissues was well retained through 48 h after
[3H]BMS-753493 administration whereas that of normal tissues
dropped quickly (Table 1), resulting in 2- to 12-fold higher
[3H]BMS-753493 radioactivity in FRþ tumors compared to
normal tissues except intestine/content at 48 h post dose (Table 1).3.2. QWBA after administration of [3H]BMS-748285
Similarly, [3H]BMS-748285-derived radioactivity was extensively
distributed following i.v. administration of [3H]BMS-748285. The
tissues that had the highest radioactivity were the intestinal tract/
content, liver, kidney, heart, bone marrow and tumors. Very little
radioactivity was observed in the brain and spinal cord (Fig. 4 and
Table 1). Likewise, heterogeneous distribution of
[3H]BMS-748285 derived radioactivity was observed in both
FRþ and FR– tumor tissues, indicating that the drug was not
well perfused in the tumors (Fig. 3). In contrast to
[3H]BMS-753493 observation, no differential distribution of
[3H]BMS-748285 radioactivity into 98M109 versus M109 tumors
(o 2.3-fold, Table 1). Therefore, no preferential targeting of
[3H]BMS-748285 into the FRþ tumors relative to FR– tumors
observed. However, [3H]BMS-748285-derived radioactivity in
Figure 3 Autoradiograms of tumors after dosing with [3H]BMS-753493. The representative autoradiograms of tumor following i.v. doses
(2.2 nmol/kg or 4 mg/kg) of [3H]BMS-753493 to tumor-bearing mice at 24 and 48 h. The sections were to compare radioactivity distribution in
M109 (FR–) and 98M109 (FRþ) tumors. Details of whole-body autoradiography are described in the Section of Materials and methods.
Table 1 Radioactivity determined by QWBA in tumors and major mouse tissues after i.v. administration of [3H]BMS-753493 and
[3H]BMS-748285 to the tumor-bearing mice.
Radioactivity in tissue (μg-eq. per gram tissue)
Tissue [3H]BMS-753493 administration [3H]BMS-748285 administration
0.5 h 2 h 24 h 48 h 0.5 h 2 h 24 h 48 h
M109 (FR) tumor 1.770.6 1.270.4 1.270.7 0.570.1 3.371.0 2.370.5 1.670.7 1.470.3
98M109 (FRþ) tumor 6.071.4 NC 4.172.2 2.371.1 6.371.5 4.771.3 2.470.9 3.370.7
Brain 0.170.0 LLQ LLQ LLQ 0.270.2 0.170.0 0.170.0 0.170.0
Blood 4.170.5 0.470.1 LLQ LLQ 0.670.2 0.270.0 0.170.0 LLQ
Bone marrow 2.370.6 1.770.2 0.970.2 0.470.1 7.870.9 5.871.1 1.970.4 1.170.2
Heart 5.670.6 2.470.1 0.970.2 0.670.1 4.470.9 2.970.7 1.270.1 0.970.1
Liver 8.571.4 4.170.5 1.470.2 1.170.2 5.771.2 3.370.6 2.570.5 1.570.3
Lung 9.371.2 2.470.5 0.870.1 0.470.1 6.772.1 5.270.8 1.670.2 1.070.2
Kidney 11.374.5 6.073.0 1.570.3 1.470.4 8.671.7 4.870.7 2.970.6 1.470.4
Muscle 0.870.4 0.370.1 0.470.1 0.270.1 1.970.4 1.370.2 0.770.1 0.670.1
Skin 4.171.0 0.870.1 0.470.1 0.470.1 1.570.2 2.370.3 0.570.1 0.670.1
Salivary gland 3.170.5 3.170.6 1.970.3 1.470.2 7.570.9 5.870.9 3.170.3 2.570.4
Spinal cord 0.270.0 0.170.0 LLQ LLQ 0.270.1 0.170.1 0.170.0 0.170.0
Intestine contents 52.6721.7 45.8732.3 37.0726.5 4.772.7 49.4726.2 49.9729.0 28.8726.6 10.278.4
NC: sample not collected due to missed tissue slicing; LLQ: below lower limit of quantitation.
Data are shown as mean 7 SD.
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activity in the M109 tumors.3.3. Pharmacokinetics and tissue distribution after intravenous
dosing of unlabeled BMS-753493 and BMS-748285
BMS-753493 was cleared rapidly from circulation, and it was
detected in plasma at 2 h but not later time points after i.v.injection of the drug. In contrast to BMS-753493, BMS-748285
converted from the conjugate was detectable through 24 h post
dose (Fig. 5). The plasma levels of BMS-748285 after i.v.
administration of BMS-753493 were signiﬁcantly less than
those after i.v. administration of the equal molar BMS-748285
(AUC of BMS-748285: 245.9 and 645.1 ng  h/mL, C24-h:
3.2 and 13.5 ng/mL; Tables 2 and 3).
The concentrations of BMS-748285 in the tumors, heart and
kidney were measured by LC–MS/MS. The levels of BMS-
Figure 4 Autoradiograms of selected sections of mice at 48 h after
dosing with [3H]BMS-748285. The representative whole-body auto-
radiograms of tumor-bearing mice following i.v. dose (2.2 nmol/kg or
1.2 mg/kg) of [3H]BMS-748285 at 48 h. The sections were to compare
radioactivity distribution in M109 (FR–, right side) and 98M109
(FRþ, left side) tumors, and selected tissues. Details of whole-body
autoradiography are described in the Section of Materials and
methods.
Figure 5 Concentration versus time proﬁle of BMS-748285 in
mouse plasma after i.v. administration of 2.2 nmol/kg BMS-753493
or BMS-748285.
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate 465748285 in 98M109 tumors were 2.0- to 3.0-fold greater than those
in M109 tumors after i.v. administration of BMS-753493 while no
difference in BMS-748285 levels between the tumors after
administration of BMS-748285 (o1.2-fold, Table 2). However,
BMS-748285 concentrations of 98M109 tumors following i.v.
administration of BMS-753493 were similar to those of M109
following i.v. administration of BMS-748285. The concentrations
of BMS-748285 in the kidney and heart, two vital organs,
following i.v. administration of BMS-753493 are signiﬁcantly
less than those after i.v. dosing of BMS-748285 (Fig. 6). The
tissue concentrations of BMS-753493 was not detectable in all
tissue samples after dosing of BMS-753493.4. Discussion
One of the greatest challenges of anti-cancer treatment involves the
delivery of therapeutically active levels of drug to tumors while not
eliciting toxicity in non-tumor tissue. Selective drug targeting has long
been a goal of drug development and there have been numerous
investigations aimed at developing more efﬁcient systems for the site
speciﬁc delivery of drugs. This strategy has recently garnered great
excitement in the oncology community with impressive clinical
beneﬁts reported on antibody directed cytotoxic drugs including T-
DM1 and SGN-3513–15. There were also considerable efforts to take
advantage of speciﬁc folate receptors on the cancer cell surface by
conjugation of folate with highly potent anti-cancer drugs for efﬁcient
delivery5,16. 99Tc-EC20, a folate-targeted imaging agent, is in devel-
opment for the diagnosis and identiﬁcation of patients with FRþ
tumors17. Clinical study involving greater than 100 patients indicated
that there is marked selective uptake of 99Tc-EC20 in ovarian, renal,
and pituitary tumors, reﬂecting the potential for therapeutic response
through folate-targeted therapy18. The clinical proof-of-concept for FR-
targeted efﬁcacy of EC145, a conjugate of folic acid and desacetylvin-
blastine hydrazide, has been reported recently19. EC145 and pegylated
liposomal doxorubicin (PLD) showed a statistically signiﬁcant delay in
progression-free survival over standard therapy in women with
platinum-resistant ovarian cancer.
BMS-753493 contains a folate moiety and a potent epothilone
analog, BMS-748285, attached through a peptide linker. It is
designed to enable tumor-speciﬁc delivery of the highly cytotoxic
epothilone analog BMS-748285 to its site of action, resulting in the
blockade of cells in mitosis and eventual cell death. The choice of
the epothilone as “cytotoxic warhead” in the target-delivery
approach is considered ideal because the mechanism of action of
epothilones (microtubule stabilization) is validated as capable of
producing clinical beneﬁts20–22. In addition, the selective cytotoxi-
city of epothilones against proliferating relative to non-proliferating
cells (except neurons) reduces the likelihood of receptor-mediated
normal tissue toxicity in those tissues that do express FR. Lack of
FR expression in neurons reduces the likelihood of neuropathy,
which is a key dose-limiting toxicity speciﬁc to this class of
cytotoxic agents23,24. Finally, the molecular potency of BMS-
748285 (IC50o1 nmol/L) maximizes the potential to effect cell kill
with the delivery of a limited number of drug molecules12.
In this study, we demonstrated modestly selective uptake and
retention of BMS-753493 and BMS-748285 in FR-postive 98M109
tumors over FR-negative M109 tumors and normal tissues after
administration of the folate-epothilone conjugate. This conclusion
Table 3 Conversion of BMS-753493 to BMS-748285 in
plasma of mice dosed IV with BMS-753493 or BMS-748285.
i.v. Dose BMS-753493
(MW 1569.7)
BMS-748285
(MW 536.7)
Dose (mg/kg) 4.0 1.2
Dose (mmol/kg) 2.55 2.24
AUC of BMS-
748285 (ng  h/mL)a
245.9736.1 645.1782.6
Exposure of BMS-
748285 (%)b
33% NC
aArea under the curve (AUC) was calculated based on simple
trapezoidal rule in excel.
bExposure of BMS-748285 was estimated by comparing the
AUC values of BMS-748285 in plasma after dosing of BMS-
753493 with that after dosing of BMS-748285.
Table 2 BMS-748285 concentrations determined by LC–MS/MS in tumors, kidney, and heart after i.v. administration of BMS-753493
or BMS-748285 to the tumor-bearing mice.
BMS-748285 concentration
Treatment Time (h) Plasma (ng/mL) M109 tumor (FR)
(mg/g tissue)
98M109 tumor (FRþ)
(mg/g tissue)
Kidney
(mg/g tissue)
Heart
(mg/g tissue)
BMS-753493 2 21.272.5 0.1070.03 0.3070.10 1.7370.15 0.1770.04
6 14.073.0 0.1670.01 0.3570.05 1.2270.12 0.1870.03
24 3.270.4 0.0970.01 0.1870.07 0.4170.05 0.1170.02
BMS-748285 2 55.274.7 0.2570.02 0.2970.11 3.3670.09 0.9370.13
6 30.277.7 0.2670.07 0.2770.05 2.6370.13 0.6170.17
24 13.572.0 0.2470.02 0.2470.03 1.3870.04 0.3370.07
Data are shown as mean 7 SD.
Hong Shen et al.466was based on (1) [3H]BMS-753493 radioactivity concentrations in
98M109 tumors being higher than those in M109 tumors after
administration of [3H]BMS-753493, and no difference observed in
the radioactivity between 98M109 and M109 tumors following
[3H]BMS-748285 dosing; (2) BMS-748285 concentrations in
98M109 tumor tissue being signiﬁcantly greater than those in
M109 following administration of unlabeled BMS-953493 but not
BMS-748285; and (3) heart and liver, two vital normal organs,
displaying lower levels of BMS-748285 when BMS-753493 was
injected compared with equal molar BMS-748285 administration.
Based on these facts, we hypothesize the folate receptor over-
expressed on the surface of cancer cells enable selective uptake of
the epothilone folate conjugate, BMS-753493, into FR-positive
tumors. Therefore, BMS-753493 may have improved safety margin
over the unconjugated epothilone BMS-748285. However, the
folate epothilone conjugate does not appear to markedly enhance
delivery to FR-positive tumors compared to the epothilone itself.
QWBA studies showed that the radioactivity derived from either
[3H]BMS-753493 or [3H]BMS-748285 in mice was extensively
distributed to a large variety of tissues. In addition to tumor cells,
the high levels of BMS-753493 and BMS-748285 radioactivity was
detected in gastrointestinal tract and content, liver, kidney, heart and
bone marrow (Figs. 2 and 4, Table 1). The highest radioactivity
concentrations in those tissues were observed at 0.5 h post dose. BMS-
748285 has high lipophilic property, which allows rapid penetration
into tissues. The wide tissue distribution of [3H]BMS-753493 derived
radioactivity may reﬂect the nonspeciﬁc release of active epothilone
after disulﬁde exchange in plasma. The steady-state volume distribution(Vdss) values of BMS-753493 were small when tested across preclinical
species whereas BMS-748285 has large Vdss (data on ﬁle but not
shown). Autoradiograms showed that radioactivity in the center area of
tumors were lower than that in the edge area of tumors (Fig. 3). This is
most likely due to lack of tumor vascularization and blood supply in
the center region.
QWBA studies showed that [3H]BMS-753493 derived radioactivity
was well retained in FR over-expressing tumors versus FR-negative
tumors. Consistently, LC–MS/MS experiments demonstrated that the
levels of BMS-748285 in 98M109 tumors were greater than those in
M109 after administration of BMS-753493 (Table 2). The tumor
concentrations of drug related radioactivity as listed in Table 1 were
higher than the BMS-748285 levels in 98M109 tumors when measured
by LC-MS assay (Table 2), although the radioactivity was predomi-
nantly BMS-748285 related. This can be explained by a difference in
methodology; only the peripheral region of tumor tissue was used to
calculate the radioactivity concentration in QWBA due to heterogeneity
observed in tumor radioactivity distribution whereas the whole tumor
tissue was homogenized for LC–MS/MS analysis. These observations
support the involvement of folate receptor in the tumor uptake of the
epothilone after dosing of the epothilone folate conjugate, and such
preferential delivery is likely a result of folate receptor expression
differences rather than of physiological or histological differences
among the tumors and normal tissues.
The tissue distribution of BMS-753493 and BMS-748285 may be
affected by ATP-binding cassette (ABC) efﬂux transporters such as
P-glycoprotein (P-gp). Radioactivity of [3H]BMS-753493 and
[3H]BMS-748285 in the brain was lower as compared to blood
and other tissues, even below the detection level at certain time
points, indicating very poor penetration into brain despite both
compounds showing wide distribution into other normal tissues. In a
different study, we found out that both BMS-753493 and BMS-
748285 were substrates for P-gp using human MDR1 transfected
cell models and P-gp knockout mice (unpublished data).
Although preferential delivery to FR-positive tumors was
demonstrated, the magnitude of selectivity versus FR-negative
tumors was not very high (3- to 5-fold). We suspect the modest
differential distribution was at least in part due to inadequate linker
technology. The disulﬁde bond readily reacts with cellular and
circulating thiol pool including cysteine, glutathione, and free
thiols in plasma including cysteine-34 of serum albumin25. This
disulﬁde exchange releases free epothilone BMS-748285. In fact,
it was estimated that 33% of the epothilone conjugate was
converted to BMS-748285 in circulation from the PK data
(Table 3). The nonspeciﬁc cleavage in turn diminished the
targeting speciﬁcity of the folate conjugate.
Figure 6 Concentrations of BMS-748285 in the kidney (A) and heart (B) after i.v. administration of 2.2 nmol/kg BMS-753493 or BMS-748285.
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate 4675. Conclusions
In summary, this study has demonstrated that BMS-753493, an
epothilone folate conjugate, preferentially distributed the active
epothilone into FR over-expressing 98M109 tumor over FR-
negative tumors and tissues, compared to epothilone administra-
tion. The epothilone folate conjugate reduced systemic exposure to
free epothilone and decreased cellular penetration into FR-negative
tumors and tissues. The preferential distribution implies the folate
conjugate might improve therapeutic margin in the treatment of
tumors over-expressing folate receptors.
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